View ValuationTvardi Therapeutics 将来の成長Future 基準チェック /06Tvardi Therapeuticsの収益は年間19.4%で減少すると予測されていますが、年間収益は年間78.3%で増加すると予想されています。EPS は年間8.9%で増加すると予想されています。主要情報-19.4%収益成長率8.89%EPS成長率Pharmaceuticals 収益成長14.5%収益成長率78.3%将来の株主資本利益率n/aアナリストカバレッジGood最終更新日12 May 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • May 03Tvardi Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $12.5 million.Tvardi Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $12.5 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offeringお知らせ • Mar 09Tvardi Therapeutics, Inc., Annual General Meeting, Jun 09, 2026Tvardi Therapeutics, Inc., Annual General Meeting, Jun 09, 2026.分析記事 • Jan 29Is Tvardi Therapeutics (NASDAQ:TVRD) In A Good Position To Deliver On Growth Plans?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...お知らせ • Jan 08Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical InsightsTvardi Therapeutics, Inc. provided further updates from its Phase 2 REVERT IPF clinical trial of TTI-101 in idiopathic pulmonary fibrosis (IPF), with preliminary results previously announced on October 13, 2025. Additional analysis was conducted to assess the impact of STAT3 inhibition using TTI-101 on fibrosis, inflammatory markers and pulmonary function, and this analysis was limited to patients who were exposed to the study drug for 12 weeks. Following review of pharmacokinetics and adverse events, one patient was removed from the analysis due to receiving less than 60% of the expected dosing, two patients were removed due to no measurable TTI-101 observed in the blood and no reported adverse events, and one additional patient was removed as an outlier because pulmonary function initially improved on treatment but was later severely impacted by acute bronchitis deemed unrelated to the study drug. This resulted in a dataset of 40 patients analyzed, including 16 pooled patients treated with TTI-101 and 24 patients treated with placebo. Data highlights showed that fibrosis decline was greater in patients treated with TTI-101 compared to placebo, at -9.4% versus -2.4%, respectively, based on baseline-weighted high resolution CT lung fibrosis scores that were centrally read, blinded and independently assessed. In terms of inflammation, a greater decline in IL-6 was observed among TTI-101-treated patients compared to placebo, with an even greater reduction seen in patients with higher baseline IL-6 levels; IL-6 is a key pro-inflammatory cytokine that signals through STAT3, and inhibition of STAT3 is expected to reduce downstream inflammatory signaling associated with disease. Additionally, 63% of pooled patients treated with TTI-101 demonstrated an increase in forced vital capacity (FVC) at 12 weeks compared to 46% of patients in the placebo group, and the mean FVC change in TTI-101-treated patients was -15 mL, representing a smaller decline than observed in the REVERT placebo group (-22 mL) and historical placebo groups from comparable IPF trials. The REVERT IPF Phase 2 clinical trial was a randomized, double-blind, placebo-controlled study of TTI-101 alone or in combination with nintedanib (OFEV®) in patients with IPF, designed to assess safety, pharmacokinetics and exploratory outcomes related to lung function, and Tvardi announced on October 13, 2025 that the study did not meet its goals after reviewing preliminary safety data and efficacy results.お知らせ • Oct 14Tvardi Therapeutics, Inc. Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary FibrosisTvardi Therapeutics, Inc. provided an update on preliminary data from the Phase 2 REVERT clinical trial of TTI-101 in idiopathic pulmonary fibrosis (IPF). The REVERT IPF Phase 2 clinical trial was a randomized, double-blind, placebo-controlled clinical trial of TTI- 101 alone or in addition to nintedanib (OFEV) in patients with IPF. The study was designed to assess safety, pharmacokinetics, and exploratory outcomes related to lung function. After reviewing the preliminary safety data and exploratory efficacy results, including changes in forced Vital Capacity (FVC), the Company concluded that the study did not meet its goals. Overall, 88 patients were randomized to TTI-101 400mg per day (n=30), 800mg per day (n=29) or placebo (n=29), and stratified by nintedanib use, with 58% of patients receiving concomitant therapy. Preliminary data demonstrated patients' baseline characteristics were similar across treatment arms, with the exception of% predicted FVC, which was lower in the placebo-treated patients (70.1%) compared to the TTI-101-treated arms (74.1% and 81.1%, respectively). Discontinuation rates across treatment arms were imbalanced, with lower discontinuation rates observed in the placebo group (10.3%) compared to treated arms (400mg and 800mg; 56.7% vs 62.1%, respectively). Disconuation rates among the TTI-101 population were primarily driven by gastrointestinal adverse events, with higher rates of events and discontinuations among patients on concurrent nintedanib. The study was not powered to evaluate exploratory endpoints. The number of efficacy evaluable patients with at least one baseline and on-treatment FVC measurement was placebo (n=29), 400mg (n=23), and 800mg (n=27). The numbers, however, declined by the 12-week timepoint to placebo (n=24), 400mg (n=8), or 800mg (n=13). The preliminary analysis was performed on actual FVC values; values were not modeled or imputed. Preliminary analysis of exploratory efficacy showed no statistically significant differences between placebo and treatment arms. Overall, from baseline to last visit on treatment, the proportion of patients who demonstrated FVC improvement from baseline was 41% for the placebo, and 39% and 44% for the 400mg and 800mg arms, respectively. FVC change from baseline overlapped between treatment arms, with large variability within each cohort. Notably, the placebo-treated patients' FVC decline was lower than expected compared to historical controls.New Risk • Oct 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 26% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (26% average weekly change). Earnings are forecast to decline by an average of 46% per year for the foreseeable future. Revenue is less than US$1m. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$146m net loss in 3 years).お知らせ • May 27Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Tti-101 in Idiopathic Pulmonary FibrosisTvardi Therapeutics, Inc. announced that it has completed enrollment for its lead program in a Phase 2 clinical trial of TTI-101 for patients with idiopathic pulmonary fibrosis (IPF). The REVERT IPF Phase 2 clinical trial is a randomized, double-blind, placebo-controlled clinical trial of TTI- 101 in patients suffering from IPF. Key endpoints include safety and lung function (FVC). TTI-101, is an oral, small molecule inhibitor of STAT3. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. Tvardi-101 has demonstrated a unique and powerful dual mechanism of action: inhibiting STAT3-driven proliferation while activating T-cells, resulting in reduced lung fibrosis and restored lung function in preclinical studies.Board Change • Apr 17No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Shaheen Wirk was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.業績と収益の成長予測NasdaqCM:TVRD - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2028N/A-48-92-47612/31/2027N/A-34-38-22712/31/2026N/A-27-23-2173/31/2026N/A-15-22-22N/A12/31/2025N/A-18-23-23N/A9/30/2025N/A-24-23-23N/A6/30/2025N/A-24-25-25N/A3/31/2025N/A-35-22-22N/A12/31/2024N/A-29-18-18N/A9/30/2024N/A-21-19-19N/A12/31/2023N/A-17-21-21N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: TVRD今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: TVRD今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: TVRD今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: TVRD来年は収益がないと予測されています。高い収益成長: TVRD来年は収益がないと予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: TVRDの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 13:21終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Tvardi Therapeutics, Inc. 7 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8 アナリスト機関Etzer DaroutBarclaysJulian HarrisonBTIGSteven SeedhouseCantor Fitzgerald & Co.5 その他のアナリストを表示
お知らせ • May 03Tvardi Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $12.5 million.Tvardi Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $12.5 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
お知らせ • Mar 09Tvardi Therapeutics, Inc., Annual General Meeting, Jun 09, 2026Tvardi Therapeutics, Inc., Annual General Meeting, Jun 09, 2026.
分析記事 • Jan 29Is Tvardi Therapeutics (NASDAQ:TVRD) In A Good Position To Deliver On Growth Plans?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
お知らせ • Jan 08Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical InsightsTvardi Therapeutics, Inc. provided further updates from its Phase 2 REVERT IPF clinical trial of TTI-101 in idiopathic pulmonary fibrosis (IPF), with preliminary results previously announced on October 13, 2025. Additional analysis was conducted to assess the impact of STAT3 inhibition using TTI-101 on fibrosis, inflammatory markers and pulmonary function, and this analysis was limited to patients who were exposed to the study drug for 12 weeks. Following review of pharmacokinetics and adverse events, one patient was removed from the analysis due to receiving less than 60% of the expected dosing, two patients were removed due to no measurable TTI-101 observed in the blood and no reported adverse events, and one additional patient was removed as an outlier because pulmonary function initially improved on treatment but was later severely impacted by acute bronchitis deemed unrelated to the study drug. This resulted in a dataset of 40 patients analyzed, including 16 pooled patients treated with TTI-101 and 24 patients treated with placebo. Data highlights showed that fibrosis decline was greater in patients treated with TTI-101 compared to placebo, at -9.4% versus -2.4%, respectively, based on baseline-weighted high resolution CT lung fibrosis scores that were centrally read, blinded and independently assessed. In terms of inflammation, a greater decline in IL-6 was observed among TTI-101-treated patients compared to placebo, with an even greater reduction seen in patients with higher baseline IL-6 levels; IL-6 is a key pro-inflammatory cytokine that signals through STAT3, and inhibition of STAT3 is expected to reduce downstream inflammatory signaling associated with disease. Additionally, 63% of pooled patients treated with TTI-101 demonstrated an increase in forced vital capacity (FVC) at 12 weeks compared to 46% of patients in the placebo group, and the mean FVC change in TTI-101-treated patients was -15 mL, representing a smaller decline than observed in the REVERT placebo group (-22 mL) and historical placebo groups from comparable IPF trials. The REVERT IPF Phase 2 clinical trial was a randomized, double-blind, placebo-controlled study of TTI-101 alone or in combination with nintedanib (OFEV®) in patients with IPF, designed to assess safety, pharmacokinetics and exploratory outcomes related to lung function, and Tvardi announced on October 13, 2025 that the study did not meet its goals after reviewing preliminary safety data and efficacy results.
お知らせ • Oct 14Tvardi Therapeutics, Inc. Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary FibrosisTvardi Therapeutics, Inc. provided an update on preliminary data from the Phase 2 REVERT clinical trial of TTI-101 in idiopathic pulmonary fibrosis (IPF). The REVERT IPF Phase 2 clinical trial was a randomized, double-blind, placebo-controlled clinical trial of TTI- 101 alone or in addition to nintedanib (OFEV) in patients with IPF. The study was designed to assess safety, pharmacokinetics, and exploratory outcomes related to lung function. After reviewing the preliminary safety data and exploratory efficacy results, including changes in forced Vital Capacity (FVC), the Company concluded that the study did not meet its goals. Overall, 88 patients were randomized to TTI-101 400mg per day (n=30), 800mg per day (n=29) or placebo (n=29), and stratified by nintedanib use, with 58% of patients receiving concomitant therapy. Preliminary data demonstrated patients' baseline characteristics were similar across treatment arms, with the exception of% predicted FVC, which was lower in the placebo-treated patients (70.1%) compared to the TTI-101-treated arms (74.1% and 81.1%, respectively). Discontinuation rates across treatment arms were imbalanced, with lower discontinuation rates observed in the placebo group (10.3%) compared to treated arms (400mg and 800mg; 56.7% vs 62.1%, respectively). Disconuation rates among the TTI-101 population were primarily driven by gastrointestinal adverse events, with higher rates of events and discontinuations among patients on concurrent nintedanib. The study was not powered to evaluate exploratory endpoints. The number of efficacy evaluable patients with at least one baseline and on-treatment FVC measurement was placebo (n=29), 400mg (n=23), and 800mg (n=27). The numbers, however, declined by the 12-week timepoint to placebo (n=24), 400mg (n=8), or 800mg (n=13). The preliminary analysis was performed on actual FVC values; values were not modeled or imputed. Preliminary analysis of exploratory efficacy showed no statistically significant differences between placebo and treatment arms. Overall, from baseline to last visit on treatment, the proportion of patients who demonstrated FVC improvement from baseline was 41% for the placebo, and 39% and 44% for the 400mg and 800mg arms, respectively. FVC change from baseline overlapped between treatment arms, with large variability within each cohort. Notably, the placebo-treated patients' FVC decline was lower than expected compared to historical controls.
New Risk • Oct 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 26% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (26% average weekly change). Earnings are forecast to decline by an average of 46% per year for the foreseeable future. Revenue is less than US$1m. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$146m net loss in 3 years).
お知らせ • May 27Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Tti-101 in Idiopathic Pulmonary FibrosisTvardi Therapeutics, Inc. announced that it has completed enrollment for its lead program in a Phase 2 clinical trial of TTI-101 for patients with idiopathic pulmonary fibrosis (IPF). The REVERT IPF Phase 2 clinical trial is a randomized, double-blind, placebo-controlled clinical trial of TTI- 101 in patients suffering from IPF. Key endpoints include safety and lung function (FVC). TTI-101, is an oral, small molecule inhibitor of STAT3. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. Tvardi-101 has demonstrated a unique and powerful dual mechanism of action: inhibiting STAT3-driven proliferation while activating T-cells, resulting in reduced lung fibrosis and restored lung function in preclinical studies.
Board Change • Apr 17No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Shaheen Wirk was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.